Pharmacokinetics of Co-Suspension Delivery Technology Budesonide/Glycopyrronium/Formoterol Fumarate Dihydrate (BGF MDI) and Budesonide/Formoterol Fumarate Dihydrate (BFF MDI) Fixed-Dose Combinations Compared With an Active Control: A Phase 1, Randomized, Single-Dose, Crossover Study in Healthy Adults

Andrea Maes, Paolo DePetrillo, Shahid Siddiqui, Colin Reisner, Paul Dorinsky, Andrea Maes, Paolo DePetrillo, Shahid Siddiqui, Colin Reisner, Paul Dorinsky

Abstract

This randomized, phase 1, single-dose, crossover study (NCT02189304) compared the 12-hour pharmacokinetic (PK) and safety profiles of budesonide/glycopyrronium/formoterol fumarate dihydrate metered dose inhaler (BGF MDI) 320/14.4/10 μg and budesonide/formoterol fumarate dihydrate (BFF) MDI 320/10 μg (both formulated using innovative co-suspension delivery technology) to an active comparator (budesonide/formoterol fumarate dihydrate dry powder inhaler [BUD/FORM DPI] 320/9-μg delivered dose) in healthy adults. The potential for PK interaction between glycopyrronium and budesonide/formoterol within BGF MDI was assessed. Of 72 subjects randomized, 59 completed treatment. Systemic budesonide exposure (primary objective) based on area under the plasma drug concentration-time curve 0-12 hours (AUC0-12 ; % coefficient of variation) was 1598.38 (49.7), 1657.09 (50.4), and 1276.75 (70.4) pg·h/mL for BGF MDI, BFF MDI, and BUD/FORM DPI, respectively; and formoterol exposure (AUC0-12 [% coefficient of variation]) was 39.16 (45.9), 39.53 (40.5), and 23.24 (59.2) pg·h/mL, respectively. BGF MDI and BFF MDI were bioequivalent for budesonide and formoterol. All treatments were well tolerated. While systemic exposure to budesonide and formoterol was higher for BGF MDI and BFF MDI than for BUD/FORM DPI, there were no appreciable differences in the incidence of pharmacologically predictable adverse events. This, coupled with the absence of PK interactions, suggests the BGF MDI safety profile will be comparable to BUD/FORM DPI.

Keywords: COPD; co-suspension delivery technology; fixed-dose combination; metered dose inhaler; pharmacokinetics.

© 2018 The Authors. Clinical Pharmacology in Drug Development Published by Wiley Periodicals, Inc. on behalf of The American College of Clinical Pharmacology.

Figures

Figure 1
Figure 1
Arithmetic mean (±SE) plasma drug concentration‐time profile of (A) budesonide, (B) formoterol, and (C) glycopyrronium (PK population). BFF, budesonide/formoterol fumarate dihydrate; BGF, budesonide/glycopyrronium/formoterol fumarate dihydrate; BUD/FORM, budesonide/formoterol fumarate dihydrate; DPI, dry powder inhaler; MDI, metered dose inhaler; PK, pharmacokinetic; SE, standard error.
Figure 2
Figure 2
Relative bioequivalence of (A) budesonide and (B) formoterol in BGF MDI and BFF MDI (ratio of geometric least squares means [90%CI] for AUC0‐12 and Cmax; PK population). AUC0‐12, area under the plasma drug concentration‐time curve from 0‐12 hours; BFF, budesonide/formoterol fumarate dihydrate; BGF, budesonide/glycopyrronium/formoterol fumarate dihydrate; CI, confidence interval; Cmax, maximum observed plasma concentration; LSM, least squares mean; MDI, metered dose inhaler; PK, pharmacokinetic.

References

    1. European Respiratory Society . European Lung White Book. 2013. . Accessed December 14, 2017.
    1. Lozano R, Naghavi M, Foreman K, et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012;380(9859):2095–2128.
    1. World Health Organization . Chronic obstructive pulmonary disease (COPD) Fact sheet. 2017. . Accessed June 13, 2017.
    1. Global Initiative for Chronic Obstructive Lung Disease . Global Strategy for the Diagnosis, Management and Prevention of COPD. 2018. . Accessed November 15, 2017.
    1. Calverley P, Vlies B. A rational approach to single, dual and triple therapy in COPD. Respirology. 2016;21(4):581–589.
    1. National Institute for Health and Care Excellence . Chronic obstructive pulmonary disease in over 16s: diagnosis and management (CG101). 2010. . Accessed June 13, 2017.
    1. Frith PA, Thompson PJ, Ratnavadivel R, et al. Glycopyrronium once‐daily significantly improves lung function and health status when combined with salmeterol/fluticasone in patients with COPD: the GLISTEN study–a randomised controlled trial. Thorax. 2015;70(6):519–527.
    1. Siler TM, Kerwin E, Singletary K, Brooks J, Church A. Efficacy and safety of umeclidinium added to fluticasone propionate/salmeterol in patients with COPD: results of two randomized, double‐blind studies. COPD. 2016;13(1):1–10.
    1. Singh D, Papi A, Corradi M, et al. Single inhaler triple therapy versus inhaled corticosteroid plus long‐acting beta2‐agonist therapy for chronic obstructive pulmonary disease (TRILOGY): a double‐blind, parallel group, randomised controlled trial. Lancet. 2016;388(10048):963–973.
    1. Lipson DA, Barnacle H, Birk R, et al. FULFIL trial: once‐daily triple therapy for patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2017;196(4):438–446.
    1. Vestbo J, Papi A, Corradi M, et al. Single inhaler extrafine triple therapy versus long‐acting muscarinic antagonist therapy for chronic obstructive pulmonary disease (TRINITY): a double‐blind, parallel group, randomised controlled trial. Lancet. 2017;389(10082):1919–1929.
    1. Vestbo J, Anderson JA, Calverley PM, et al. Adherence to inhaled therapy, mortality and hospital admission in COPD. Thorax. 2009;64(11):939–943.
    1. Yu AP, Guérin A, Ponce de Leon D, et al. Therapy persistence and adherence in patients with chronic obstructive pulmonary disease: multiple versus single long‐acting maintenance inhalers. J Med Econ. 2011;14(4):486–496.
    1. Yu AP, Guérin A, Ponce de Leon D, et al. Clinical and economic outcomes of multiple versus single long‐acting inhalers in COPD. Respir Med. 2011;105(12):1861–1871.
    1. Lechuga‐Ballesteros D, Noga B, Vehring R, Cummings RH, Dwivedi SK. Novel cosuspension metered‐dose inhalers for the combination therapy of chronic obstructive pulmonary disease and asthma. Future Med Chem. 2011;3(13):1703–1718.
    1. Vehring R, Lechuga‐Ballesteros D, Joshi V, Noga B, Dwivedi SK. Cosuspensions of microcrystals and engineered microparticles for uniform and efficient delivery of respiratory therapeutics from pressurized metered dose inhalers. Langmuir. 2012;28(42):15015–15023.
    1. Doty A, Schroeder J, Vang K, et al. Drug delivery from an innovative LAMA/LABA co‐suspension delivery technology fixed‐dose combination MDI: evidence of consistency, robustness, and reliability. AAPS PharmSciTech. 2018;19(2):837–844.
    1. Tzelepis G, Komanapolli S, Tyler D, Vega D, Fulambarker A. Comparison of nebulized glycopyrrolate and metaproterenol in chronic obstructive pulmonary disease. Eur Respir J. 1996;9(1):100‐103.
    1. Mirakhur RK, Dundee JW. Glycopyrrolate: pharmacology and clinical use. Anaesthesia. 1983;38(12):1195–1204.
    1. Bartels C, Looby M, Sechaud R, Kaiser G. Determination of the pharmacokinetics of glycopyrronium in the lung using a population pharmacokinetic modelling approach. Br J Clin Pharmacol. 2013;76(6):868–879.
    1. Sechaud R, Renard D, Zhang‐Auberson L, Motte SL, Drollmann A, Kaiser G. Pharmacokinetics of multiple inhaled NVA237 doses in patients with chronic obstructive pulmonary disease (COPD). Int J Clin Pharmacol Ther. 2012;50(2):118–128.
    1. Cada DJ, Levien T, Baker DE. Formoterol fumarate inhalation powder. Hosp Pharm. 2001;36(7):753–767.
    1. Jonsson G, Astrom A, Andersson P. Budesonide is metabolized by cytochrome P450 3A (CYP3A) enzymes in human liver. Drug Metab Dispos. 1995;23(1):137–142.
    1. Szefler SJ. Pharmacodynamics and pharmacokinetics of budesonide: a new nebulized corticosteroid. J Allergy Clin Immunol. 1999;104(4 Pt 2):175–183.
    1. Williams EJ. Experimental designs balanced for the estimation of residual effects of treatments. Aust J Sci Res B. 1949;2(2):149–168.
    1. AstraZeneca UK Limited . Symbicort Turbohaler 200/6 Inhalation Powder. Summary of Product Characteristics. 2017. . Accessed February 22, 2018.
    1. Weisfeld L, Shu Y, Shah TP. Bioequivalence of budesonide plus formoterol (BF) Spiromax® and BF Turbohaler® (with and without charcoal block) in healthy volunteers. Int J Clin Pharmacol Ther. 2015;53(7):593–602.
    1. Laube BL, Janssens HM, de Jongh FHC, et al. What the pulmonary specialist should know about the new inhalation therapies. Eur Respir J. 2011;37(6):1308–1331.
    1. Molimard M, Raherison C, Lignot S, et al. Chronic obstructive pulmonary disease exacerbation and inhaler device handling: real‐life assessment of 2935 patients. Eur Respir J. 2017;49(2):1601794.
    1. Rosenhall L, Elvstrand A, Tilling B, et al. One‐year safety and efficacy of budesonide/formoterol in a single inhaler (Symbicort Turbuhaler) for the treatment of asthma. Respir Med. 2003;97(6):702–708.
    1. Szafranski W, Cukier A, Ramirez A, et al. Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease. Eur Respir J. 2003;21(1):74–81.
    1. Morice AH, Peterson S, Beckman O, Osmanliev D. Therapeutic comparison of a new budesonide/formoterol pMDI with budesonide pMDI and budesonide/formoterol DPI in asthma. Int J Clin Pract. 2007;61(11):1874–1883.
    1. Aalbers R, Ayres J, Backer V, et al. Formoterol in patients with chronic obstructive pulmonary disease: a randomized, controlled, 3‐month trial. Eur Respir J. 2002;19(5):936–943.
    1. Haahtela T, Järvinen M, Kava T, et al. Comparison of a beta 2‐agonist, terbutaline, with an inhaled corticosteroid, budesonide, in newly detected asthma. N Engl J Med. 1991;325(6):388–392.
    1. Campbell SC, Criner GJ, Levine BE, et al. Cardiac safety of formoterol 12μg twice daily in patients with chronic obstructive pulmonary disease. Pulm Pharmacol Ther. 2007;20(5):571–579.
    1. Rosenkranz B, Rouzier R, Kruse M, et al. Safety and tolerability of high‐dose formoterol (via Aerolizer) and salbutamol in patients with chronic obstructive pulmonary disease. Respir Med. 2006;100(4):666–672.
    1. Reisner C, Fabbri LM, Kerwin EM, et al. A randomized, seven‐day study to assess the efficacy and safety of a glycopyrrolate/formoterol fumarate fixed‐dose combination metered dose inhaler using novel Co‐Suspension™ Delivery Technology in patients with moderate‐to‐very severe chronic obstructive pulmonary disease. Respir Res. 2017;18(1):8.
    1. Darken P, DePetrillo P, Reisner C, Rose ES, Dorinsky P. The pharmacokinetics of three doses of budesonide/glycopyrronium/formoterol fumarate dihydrate metered dose inhaler compared with active controls: a phase I randomized, single‐dose, crossover study in healthy adults. Pulm Pharmacol Ther. 2018;50:11–18.
    1. Lähelmä S, Sairanen U, Haikarainen J, et al. Equivalent lung dose and systemic exposure of budesonide/formoterol combination via Easyhaler and Turbuhaler. J Aerosol Med Pulm Drug Deliv. 2015;28(6):462–473.
    1. Eklund A, Tronde A, Johannes‐Hellberg I, Gillen M, Borgström L. Pharmacokinetics of budesonide and formoterol administered via a series of single‐drug and combination inhalers: four open‐label, randomized, crossover studies in healthy adults. Biopharm Drug Dispos. 2008;29(7):382–395.
    1. Battisti WP, Wager E, Baltzer L, et al. Good publication practice for communicating company‐sponsored medical research: GPP3. Ann Intern Med. 2015;163(6):461–464.

Source: PubMed

Sponsors and Collaborators

Medical Conditions

Drug Interventions

3
Subscribe